Mount Sinai is rolling out face‑scan check‑ins with CLEAR1 across its hospitals and clinics, promising faster check‑ins and fewer duplicate records while prompting privacy debate.

Morehouse landed a $5M NSF share to build a campus site for Horizon, bringing leadership‑class AI and research compute to the Atlanta HBCU and partner schools.

Hong Kong’s RedotPay is reportedly weighing a New York IPO that could raise more than $1 billion and value the company north of $4 billion as regulators ready licenses. Investors will be watching reserves and redemption rules closely.

An Austin business court heard arguments this week over whether CrowdStrike is really headquartered here as GoSecure accuses the company of using stolen trade secrets. The judge took the matter under advisement.

A northwest Missouri fossil hunter recovered a 92‑pound bone he believes is a Columbian mammoth femur; CT scans and radiocarbon dating are planned to verify the claim.

Alveus Therapeutics extended its Series A to $197M and moved its U.S. headquarters to Philadelphia to accelerate development of its obesity drug programs.

Novo Nordisk partnered with Boston startup Vivtex to develop next‑generation oral obesity and diabetes pills. The deal could deliver up to $2.1 billion to the local biotech.

UC Santa Cruz researchers found fishermen's satellite tracks can flag tuna distribution shifts faster than sea‑surface temperatures. That could give fisheries earlier warnings of marine heatwave impacts.

UTSA researchers and maintainers warn AI-generated code is hallucinating package names, creating a predictable new supply-chain attack dubbed “slopsquatting.”

UF researchers retooled tomato carotenoids with a pepper gene, producing orange fruit higher in beta‑carotene that could help address vitamin A deficiency.

Chicago’s Letter AI landed a $40M Series B led by Battery Ventures and launched Letter Compass to bring AI coaching into live deals. The company says it will triple hiring this year.

Mount Sinai‑affiliated clinics in Manhattan are using an FDA‑cleared AI from BrightHeart to flag fetal heart abnormalities, a move studies show boosts detection and shortens review time.

Nobel laureate Richard Axel stepped down as co‑director of Columbia’s Zuckerman Institute after DOJ records linked him to Jeffrey Epstein. Columbia said it found no evidence of legal violations but accepted his resignation.